Article

Humoral Immune Response Against XBB.1.5 and BQ.1.1 SARS-COV-2 Variants of a Fourth Dose of PHH-1V Vaccine in Adult Subject: Preliminary Results of HIPRA-HH-2 Extension Study

2023-09-28

Abstract excerpt

<p>Background: In 2023, COVID-19 cases were mainly associated with BQ.1 and XBB.1.5 subvariants, causing mostly mild cases and boosting hybrid immunity throughout the population. PHH-1V (HIPRA COVID-19 vaccine) is a bivalent recombinant protein vaccine based on the receptor binding domain of Beta and Alpha SARS-CoV-2 variants, which is authorised for commercialisation in the EU (March 30th, 2023) and UK (July 31s...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0bdf09bb-9219-5e8f-8924-543f0bb81be0
DOI: 10.2139/ssrn.4586148

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Humoral Immune Response Against XBB.1.5 and BQ.1.1 SARS-COV-2 Variants of a Fourth Dose of PHH-1V Vaccine in Adult Subject: Preliminary Results of HIPRA-HH-2 Extension StudyDOI 10.2139/ssrn.4586148Read

Immunogenicity and safety of an Omicron XBB.1.16 adapted vaccine for COVID-19: Interim results from a randomized, controlled, non-inferiority clinical trialSemantic proximity Read

Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trialSemantic proximity Read

Humoral Immune Response Against Sars-Cov-2 Variants (Omicron Ba.1, Ba.4/5, Beta and Delta) of Phh-1v Booster Vaccine in Subjects Previously Vaccinated with a Mrna Vaccine. Results of a Randomised Controlled Trial Up to 6 MonthsSemantic proximity Read

Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trialSemantic proximity Read

SAFETY AND IMMUNOGENICITY OF A PHH-1V BOOSTER DOSE AFTER DIFFERENT PRIME VACCINATION SCHEMES AGAINST COVID-19: PHASE III CLINICAL TRIAL FINAL RESULTS UP TO ONE YEARSemantic proximity Read

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1Semantic proximity Read

Immunogenicity and Safety of PHH-1V COVID-19 Vaccine as a Heterologous Booster in AdolescentsSemantic proximity Read

Determinants of antibody responses to two doses of ChAdOx1 nCoV-19 or BNT162b2 and a subsequent booster dose of BNT162b2 or mRNA-1273: population-based cohort study (COVIDENCE UK)Semantic proximity Read

XBB .1.5 neutralizing antibodies upon bivalent COVID ‐19 vaccination are similar to XBB but lower than BQ .1.1Semantic proximity Read

Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 Protein VaccineSemantic proximity Read

Safety and Immunogenicity of XBB.1.5-Containing mRNA VaccinesSemantic proximity Read

Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primatesSemantic proximity Read